Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial

Casson, Peter R.; Santoro, Nanette; Elkind‐Hirsch, Karen; Carson, Sandra Ann; Hornsby, Peter J.; Abraham, Guy E.; Buster, John E.

doi:10.1016/s0015-0282(98)00121-6

Cited by 166 publications

(125 citation statements)

References 13 publications

Supporting

Mentioning

114

Contrasting

Unclassified

Order By: Relevance

“…Given the current findings in the female participants, those therapeutic interventions in patients with anorexia nervosa may be relevant to patients with CF. There is also evidence to support the role of DHEA in the modulation of the skeletal IGF-I regulatory system that may have therapeutic implications for this group [27].…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Relationship between insulin-like growth factor I, dehydroepiandrosterone sulfate and proresorptive cytokines and bone density in cystic fibrosis

et al. 2006

View full text Add to dashboard Cite

Introduction-Patients with cystic fibrosis (CF) are known to be at risk for early osteoporosis, and the mechanisms that mediate bone loss are still being delineated. The aim of the present investigation was to investigate if a correlation exists in these patients between skeletal measurements by dual-energy x-ray absorptiometry (DXA) and two anabolic factors, dehydroepiandrosterone (DHEA) and insulin-like growth factor I (IGF-I), and proresorptive factors such as the cytokines interleukin-1β, tumor necrosis factor α, and interleukin-6.

show abstract

Section: Discussionmentioning

confidence: 98%

“…Previous studies have shown that IGF-I concentrations are low in patients with CF [25,26], but the relevance of this finding to skeletal physiology has not been examined to date. The anabolic effects of DHEA on the skeleton appear to be mediated through the skeletal IGF-I system [22,27].…”

Section: Introductionmentioning

confidence: 99%

Relationship between insulin-like growth factor I, dehydroepiandrosterone sulfate and proresorptive cytokines and bone density in cystic fibrosis

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Examining the effects of DHEA replacement in subjects with previously documented hypercholesterolemia did not lead to the finding of significant effects of the treatment in a 12-week randomized placebo-controlled study using 25 mg/day oral DHEA (127). On the other hand, some studies reported significant effects of DHEA on blood lipids (6, 11, 125,126,128,132,133). All the studies reporting significant effects of DHEA on lipid-lipoprotein levels found a slight but significant decrease in HDL-cholesterol levels, which appeared to occur mostly in women (11,125,126,128,132,133).…”

Section: Exogenous Dheamentioning

confidence: 95%

Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies

Tchernof

Labrie

2004

European Journal of Endocrinology

152

100

View full text Add to dashboard Cite

The age-related decline in serum dehydroepiandrosterone (DHEA) and its sulfated ester (DHEA-S) has suggested that a relative deficiency of these steroids may be causally related to the development of chronic diseases generally associated with aging, including insulin resistance, obesity, cardiovascular disease, cancer, reductions of the immune defense, depression and a general deterioration in the sensation of well-being. The numerous studies which have focused on the link between DHEA and cardiovascular disease have generally been inconsistent, generating much debate and controversy on this issue. The present article is an analysis of studies on the relationship between endogenous DHEA or DHEA-S, obesity and cardiovascular disease risk, as well as DHEA treatment studies. Elevated plasma levels of free DHEA are associated with reduced obesity in both men and women, and with smaller abdominal body fat accumulations in men. However, contradictory results have been reported regarding the relationships between the sulfate ester DHEA-S and adiposity. Age differences in the populations studied may have been a confounding factor in these associations. On the other hand, DHEA-S level is not a predictor of cardiovascular disease endpoints in women, and appears to be a relatively weak one in men. DHEA intervention studies suggest that the effects of DHEA on serum lipids are, at best, modest or non-significant. The uncertainty as to whether endogenous and exogenous DHEA should be considered cardioprotective is related to discrepancies in the literature on this topic. Several studies may have been plagued by methodological problems such as low power, unreliable analytical methods, confounding factors or other differences in the populations studied. As a consequence, the original reports demonstrating dramatic effects of either endogenous or exogenous DHEA on cardiovascular disease risk have never been replicated. We propose that the effects of DHEA on cardiovascular disease risk (either favorable or unfavorable) should be considered to be much more modest than previously believed.

show abstract

“…The mechanism by which DHEA exerts its effects is uncertain; however, the authors speculated it may have a role in increasing the serum concentrations of IGF-1, which in turn may improve the response to gonadotropins [15]. Previously, Casson et al studied the effect of DHEA supplementation on IGF-1 and High Density lipoprotein in postmenopausal women [16]. DHEA resulted in an increased IGF-1 at 3 months and a decreased high density lipoprotein and apolipoprotein A1 at 6 months [16].…”

Section: Published Studiesmentioning

confidence: 99%

“…Previously, Casson et al studied the effect of DHEA supplementation on IGF-1 and High Density lipoprotein in postmenopausal women [16]. DHEA resulted in an increased IGF-1 at 3 months and a decreased high density lipoprotein and apolipoprotein A1 at 6 months [16]. A prior study investigated the expression of IGF-1 in a DHEA-induced rat polycystic ovarian model: using In situ hybridization technique, the expression of IGF-1 in prenatral and small antral follicles in the DHEAtreated rats was increased (but not in large antral follicles), as was IGF-1 expression in granulosa cells in a cell-culture system [17].…”

Section: Published Studiesmentioning

confidence: 99%

Is there a role for DHEA supplementation in women with diminished ovarian reserve?

Fouany

Sharara

2013

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose Poor ovarian reserve and poor ovarian response presents a challenge to IVF centers. Dehydroepiandrosterone (DHEA) supplementation is increasingly being used by many IVF centers around the world in poor responders despite the lack of convincing data. We therefore examined the rationale for the use of DHEA in poor responders, address the relevant studies, present new data, and address its potential mechanisms of action. Methods All published articles on the role of DHEA in infertile women from 1990 to April 2013 were reviewed. Results Several studies have suggested an improvement in pregnancy rates with the use of DHEA. Potential mechanisms include improved follicular steroidogenesis, increased IGF-1, acting as a pre-hormone for follicular testosterone, reducing aneuploidy, and increasing AMH and antral follicle count. While the role of DHEA is intriguing, evidencebased recommendations are lacking. Conclusions While nearly 25 % of IVF programs use DHEA currently, large randomized prospective trials are sorely needed. Until (and if) such trials are conducted, DHEA may be of benefit in suitable, well informed, and consented women with diminished ovarian reserve.

show abstract

Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial

Cited by 166 publications

References 13 publications

Relationship between insulin-like growth factor I, dehydroepiandrosterone sulfate and proresorptive cytokines and bone density in cystic fibrosis

Relationship between insulin-like growth factor I, dehydroepiandrosterone sulfate and proresorptive cytokines and bone density in cystic fibrosis

Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies

Is there a role for DHEA supplementation in women with diminished ovarian reserve?

Contact Info

Product

Resources

About